OKYO Pharma Limited, (OKYO): Price and Financial Metrics
GET POWR RATINGS... FREE!
OKYO Stock Price Chart Interactive Chart >
OKYO Price/Volume Stats
| Current price | $2.22 | 52-week high | $6.11 |
| Prev. close | $2.32 | 52-week low | $1.61 |
| Day low | $2.21 | Volume | 3,400 |
| Day high | $2.43 | Avg. volume | 8,530 |
| 50-day MA | $2.13 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 48.33M |
OKYO Pharma Limited, (OKYO) Company Bio
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest OKYO News From Around the Web
Below are the latest news stories about OKYO PHARMA LTD that investors may wish to consider to help them evaluate OKYO as an investment opportunity.
A OKYO Pharma Limited (LON:OKYO) insider increased their holdings last yearLooking at OKYO Pharma Limited's ( LON:OKYO ) insider transactions over the last year, we can see that insiders were... |
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its interim results for the six months ended 30 September 2022. Clinical Updates: OK-101 During the past six months the Group’s primary focus has been centered on accomplishing the filing of the investigati |
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in the first quarter 2023- LONDON and NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, |
OKYO to Participate at Biotech ShowcaseLONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announced today that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at th |
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SECLONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a secondary public offering of its American Depositary Shares ("ADSs"), each of which |
OKYO Price Returns
| 1-mo | 21.35% |
| 3-mo | -2.63% |
| 6-mo | 6.73% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 16.23% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...